New protein test could spot hidden uterine disease
NCT ID NCT06864494
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at whether a protein called L-PGDS can be used to diagnose adenomyosis, a condition where uterine tissue grows into the muscle wall, causing pain and heavy bleeding. Researchers will measure L-PGDS levels in vaginal swabs, blood, and urine from 60 women with and without adenomyosis. If L-PGDS levels differ between groups, it might lead to a simple, non-invasive diagnostic test.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a simple, non-invasive diagnostic test for adenomyosis using blood or urine, potentially catching the disease earlier.
- What could go wrong
- This is a small, early-stage study (60 participants) that only measures a protein level. It may not prove useful for diagnosis, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Multiparous, non-menopausal patients aged between 40 and 55 consulting the gynecology-obstetrics department of the CHU de Nîmes for menometrorrhagia and/or pelvic pain and having an indication for total inter-ovarian hysterectomy plus healthy controls aged between 18 and 43, nulliparous, without uterine pathologies treated at the Nîmes University Hospital's assisted reproduction center for male or idiopathic infertility.
- Ages
-
18 to 57 years
- Sex
-
Female participants only
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Common inclusion criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan Adenomyosis + group: * Female. * Aged 28 (≥) to 57 (≤) years. * Non-menopausal. * Having an indication for a total inter-ovarian hysterectomy (excluding oncology). * Suffering from adenomyosis. Adenomyosis - group: * Female. * Aged 28 (≥) to 57 (≤) years. * Non-menopausal. * Having an indication for a total inter-ovarian hysterectomy (excluding oncology). * Suffering from a functional pathology other than adenomyosis. Control Group: * Female. * Aged 18 (≥) to 57 (≤) years. * Asymptomatic: absence of menometrorrhagia and pelvic pain. * Support at the medically assisted procreation (MAP) center of the Nîmes University Hospital for male or idiopathic infertility. * Indication to perform an endovaginal ultrasound as part of MAP management. * Absence of uterine pathology visualized on endovaginal ultrasound. Exclusion Criteria: * History of autoinflammatory or autoimmune disease. * History of atopic or asthmatic conditions. * History of sleep apnea syndrome. * Chronic or acute renal failure. * Liver failure * History of active neoplasia or cancer. * Taking nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or aspirin in the 15 days prior to L-PGDS concentration measurement * Undergoing estrogen-progestin hormonal contraception. Adenomyosis groups: \- Contraindication to MRI. Control Group: * Endovaginal ultrasound refused by the patient. * Presence of a functional-looking ovarian cyst on imaging (endovaginal ultrasound and/or pelvic MRI).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adenomyosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU de Nimes
RECRUITINGNîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery pelvic floor therapy stop endometriosis pain after the operation?
- Appendix: the hidden driver of endometriosis pain?
- Allergy pill put to the test against endometriosis pain
- Can ultrasound and tissue clues reveal which endometriosis lesions carry cancer risk?
- Can AI personalize exercise to ease pelvic pain?
- Can AI learn to spot endometriosis and fibroids on ultrasound?